亚太药业（002370）8月25日主力资金净流出2507.96万元

Group 1 - The core viewpoint of the news is that Asia Pacific Pharmaceutical (002370) has experienced a significant decline in revenue and net profit in its latest quarterly report, indicating potential challenges for the company moving forward [1] - As of August 25, 2025, the company's stock closed at 6.77 yuan, with a slight increase of 0.59% and a trading volume of 726,000 hands, amounting to a total transaction value of 491 million yuan [1] - The company reported total revenue of 64.55 million yuan for the first quarter of 2025, a year-on-year decrease of 42.73%, and a net profit attributable to shareholders of 7.80 million yuan, down 160.25% year-on-year [1] Group 2 - Asia Pacific Pharmaceutical has made investments in 7 companies and participated in 732 bidding projects, indicating active engagement in business development [2] - The company holds 120 trademark registrations and 78 patents, showcasing its focus on intellectual property and innovation [2] - Additionally, the company has obtained 135 administrative licenses, reflecting its compliance and operational capabilities within the pharmaceutical industry [2]